Shares of Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shot up 3.4% during trading on Thursday . The company traded as high as $0.98 and last traded at $0.97. 37,468 shares traded hands during trading, a decline of 96% from the average session volume of 1,047,134 shares. The stock had previously closed at $0.94.
Analysts Set New Price Targets
A number of analysts have weighed in on CTOR shares. Maxim Group cut Citius Oncology from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Citigroup downgraded Citius Oncology to a "hold" rating in a report on Friday, May 23rd.
Check Out Our Latest Research Report on CTOR
Citius Oncology Stock Performance
The stock has a fifty day moving average of $0.81 and a 200-day moving average of $0.98. The company has a current ratio of 0.34, a quick ratio of 0.08 and a debt-to-equity ratio of 0.08.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Hedge Funds Weigh In On Citius Oncology
An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC purchased a new position in shares of Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,699 shares of the company's stock, valued at approximately $26,000. Institutional investors own 70.52% of the company's stock.
Citius Oncology Company Profile
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Further Reading
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
